Takeda Pharmaceutical plans $725M R&D overhaul, FDA approves AbbVie's VIEKIRA XR for HCV & more — 5 GI company key notes

Here are five recent news updates on key gastroenterology and endoscopy companies.

Takeda Pharmaceutical is planning a $725 million overhaul of its research and development efforts.

United States Rep. Ted Lieu (D-Torrance) is urging Congress to tighten requirements governing medical device warnings, in light of the discovery that Olympus told U.S. executives not to issue a warning to hospitals regarding a possible deadly infection from tainted scopes.

Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment. The results found the treatment was not statistically significant.

The FDA approved AbbVie's new drug application for VIEKIRA XR extended-release tablets.

Galmed Pharmaceuticals named Ran Oren, MD, chief medical officer.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast